Will AI-powered DSP-1181 Help Put People With OCD at Ease?

Pharma Tech Outlook: Pharma Tech Magazine

Will AI-powered DSP-1181 Help Put People With OCD at Ease?

By Pharma Tech Outlook | Wednesday, August 05, 2020

Certainly, artificial intelligence (AI) is very powerful. Recently, a drug molecule has been invented by AI completely and will be utilized in the human trials across the world for treating OCD.

FREMONT, CA: Just a few days ago, a drug molecule invented completely by AI is all set to make its entry into human clinical trials for the first time, thus marking a crucial milestone for the importance of ML in medicine. As per the explanation of the researchers, the AI took only 12 months for recognizing the right molecule, a procedure that generally takes five years span for human researchers. This medicine will soon be utilized in clinical trials, which will mark the first time a drug invented by an AI will be tested on humans.

Top 10 Artificial Intelligence Solution Companies - 2019The molecule, called DSP-1181, is one of the billions of potential chemical compounds that the AI went through while respecting numerous parameters. It is a very delicate process that generally includes ample trial and error; however, it has been broadly accelerated by machine learning algorithms.

Japanese pharmaceutical company Sumitomo Dainippon Pharma and British company Exscientia worked collaboratively to make this kind of AI a reality.

Researchers are planning to conduct phase one trials in Japan, and if initial results are promising, the test will be further conducted globally.

DSP-1181 is considered a long-acting serotonin 5-HT1A receptor agonist that is used for treating OCD. In Japan, one million people suffer from this condition, while around 3 million people in the U.S are affected by this disorder.

The British company is planning to use this AI-powered approach for discovering novel treatments for other medical conditions as well. Scientists are presently working on drugs for cardiovascular disease and cancer.

The average price of research and development for a new drug is $2 billion. It is paramount to increase the efficiency of drug discovery in the future, and AI definitely plays a critical role in it.

For now, DSP-1191 is the first drug molecule designed by AI for treating human diseases.

see also: Top Healthcare AI Companies in Europe

Weekly Brief

Read Also